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Abstract
Objectives: Hyperuricemia is a metabolic condition central to gout pathogenesis. Urate exposure primes human
monocytes towards a higher capacity to produce and release IL-1β. In this study, we assessed the epigenetic
processes associated to urate-mediated hyper-responsiveness.
Methods: Freshly isolated human peripheral blood mononuclear cells or enriched monocytes were pre-treated
with solubilized urate and stimulated with LPS with or without monosodium urate (MSU) crystals. Cytokine
production was determined by ELISA. Histone epigenetic marks were assessed by sequencing immunoprecipitated
chromatin. Mice were injected intraarticularly with MSU crystals and palmitate after inhibition of uricase and urate
administration in the presence or absence of methylthioadenosine. DNA methylation was assessed by methylation
array in whole blood of 76 participants with normouricemia or hyperuricemia.
Results: High concentrations of urate enhanced the inflammatory response in vitro in human cells and in vivo in
mice, and broad-spectrum methylation inhibitors reversed this effect. Assessment of histone 3 lysine 4
trimethylation (H3K4me3) and histone 3 lysine 27 acetylation (H3K27ac) revealed differences in urate-primed
monocytes compared to controls. Differentially methylated regions (e.g. HLA-G, IFITM3, PRKAB2) were found in
people with hyperuricemia compared to normouricemia in genes relevant for inflammatory cytokine signaling.
Conclusion: Urate alters the epigenetic landscape in selected human monocytes or whole blood of people with
hyperuricemia compared to normouricemia. Both histone modifications and DNA methylation show differences
depending on urate exposure. Subject to replication and validation, epigenetic changes in myeloid cells may be a
therapeutic target in gout.
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Introduction
Urate is the end-point metabolite in purine catabolism
in humans and is regarded as an alarmin released from
disintegrating cells at times of stress or cell death [1, 2].
Higher urate concentration in the serum defines the
condition of hyperuricemia, at which point monosodium
urate (MSU) crystals can precipitate in peripheral tissues
and cause an inflammatory response. Gout is caused by
persistent hyperuricemia, a painful inflammatory arth-
ritis caused by the deposition of (MSU) crystals in the
synovial cavity [3]. MSU crystals have been shown to in-
duce IL-1β release through activation of the NLRP3
inflammasome [4]. They recruit ASC (Inflammasome
Adaptor Protein Apoptosis-Associated Speck-Like Pro-
tein Containing CARD) at the inflammasome formation
site through the polymerization of tubulin [5]. MSU
crystals alone are insufficient for a gout flare and second
signals are required to act in synergy with MSU crystals.
Such second signals can be pathogen-related ligands
such as lipopolysaccharide (LPS) [6], Pam3Cys [7], or
sterile stimuli such as fatty acids (e.g., stearate) [8], or
the C5a component of the complement [9].
Despite a widely accepted pathogenesis model for gout
stemming from long-lasting hyperuricemia that deter-
mines the formation of MSU crystals, many questions
remain to address the clinical observations of urate-
related inflammation[10]. The reasons why not all
people with hyperuricemia develop gout, or why some
people with MSU crystals in synovial fluid do not show
signs of inflammation [11], remain unknown. Genome-
wide association studies have identified hundreds of gen-
omic loci associated with serum urate levels and gout
[12–15] However, little progress has been made in un-
derstanding the genetic control of the progression from
hyperuricemia to gout [16]. Large-scale genetic studies
are likely to pinpoint additional factors that specifically
lead to gout in people with hyperuricemia. Environmen-
tal factors (e.g., dietary triggers) [17] can also contribute
to inflammation in people with hyperuricemia. More-
over, epidemiological studies suggest that MSU crystals
and soluble urate itself also play a role in signaling dan-
ger in diseases other than gout: from the low-grade in-
flammation in aging [18] to common metabolic
disorders [19] and cancer [20].
We previously described the priming effects of high
concentrations of soluble urate on primary human per-
ipheral blood mononuclear cells (PBMC)s and mono-
cytes, where a shift in cytokine production towards
elevated IL-1β concomitant with reduced IL-1Ra could
be observed [21]. In addition, we reported that PBMCs
of individuals with hyperuricemia produce higher
amounts of pro-inflammatory cytokines than normouri-
cemic controls after ex vivo stimulation [21]. This can
be reproduced in vitro by pre-treating cells with
increasing urate doses followed by washout and re-
stimulation with toll-like receptor ligands and MSU
crystals. Interestingly, the high proinflammatory capacity
coincided with a reduction in IL-1 receptor antagonist
(IL-1Ra) production [21], which is at least in part medi-
ated by AKT phosphorylation and autophagy repression
in primary human monocytes [22]. Several stimuli exert
long-term effects on innate immunity through epigenetic
modifications (a process termed trained immunity) [23].
This persistent state of immunological memory can
be induced by microbial stimuli such as Candida
albicans or β-glucan (cell wall component of C.
albicans) [24, 25], as well as sterile stimuli such as
oxidized cholesterol or phospholipids [26, 27].
A recent study performed in patients with gout high-
lights several differentially methylated loci (DML) with
relevance to inflammation [28]. DMLs were found in
known gout risk genes and candidate genes (e.g.,
SLC2A9, ABCC9), transcription factor genes (NFATC2
and MEF2C), and their regulated gene networks in leu-
kocytes. Pathway analysis of DML suggests gout patients
have altered DNA methylation levels of genes involved
in both innate and adaptive immunity pathways, with a
strong signature for Th17 differentiation and osteoclas-
togenesis [28].
In the present study, we hypothesize that urate drives
persistent proinflammatory effects through epigenetically
mediated innate immune memory and that hyperurice-
mic individuals could have altered epigenetic landscapes
in immune cells compared to normouricemic people.
We use complementary approaches aimed to establish
the molecular basis of urate-mediated proinflammatory
status of human monocytes. We show that exposure to
urate can have persistent effects in vitro, which is con-
sistent with previous data showing that monocytes of
gout patients retain their capacity to produce more cyto-
kines in the absence of hyperuricemia[7, 21]. We identify
post-translational histone modifications and DNA
methylation as molecular substrates for the effects of
hyperuricemia.
Materials and methods
A detailed version of this section is provided in the
Additional file 1.
Participants
Urate priming experiments were performed in 85 Dutch
volunteers from the Human Functional Genomics
Project (http://www.humanfunctionalgenomics.org) [29].
Experiments were approved by the Ethical Committee of
Radboud University Nijmegen (nr. 42561.091.12). The
DNA methylation study was performed in 76 individuals
(Table S1) of New Zealand Māori ancestry and was ap-
proved by the New Zealand Lower South Health and
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Disability Ethics Committee (MEC/05/10/130). Patients
or the public were not involved in the design, or con-
duct, or reporting, or dissemination of our research.
PBMC and monocyte isolation
Human PBMCs were separated using Ficoll-Paque
(Pharmacia Biotech). Monocytes were enriched using
hyperosmotic Percol solution [30] and were subse-
quently purified by negative selection using magnetic
beads (Miltenyi Biotec).
Stimulation experiments
Experiments were performed in a culture medium con-
taining RPMI 1640, supplemented with 50 μg/ml genta-
micin, 2 mM L-glutamine, 1 mM pyruvate, and 10%
human pooled serum following an in vitro urate priming
protocol described extensively elsewhere[22].
Cytokine measurements
Cytokine concentrations were determined in cell culture
supernatants using ELISA.
Animal model
Male 10–12 weeks old C57Bl/6 J mice were purchased
from Jackson Laboratories (Bar Harbor, Maine, USA).
Uricase was inhibited using oxonic acid and urate was
administered according to a previously described
protocol [22].
ChIP-sequencing preparation and analysis
DNA-histone crosslinking was performed using 1% for-
maldehyde followed by 1.25 mol/L glycine. Chromatin
was sonicated using a Diagenode Bioruptor UCD-300
and immunoprecipitated using H3K27ac or H3K4me3
antibodies (Diagenode) and protein A/G magnetic beads.
DNA was purified using QIAGEN Qiaquick MinElute
PCR purification Kit. Illumina library preparation was
done as previously described [31]. Sequencing was per-
formed using Illumina HiSeq 2000.
DNA methylation analysis
Genomic DNA was isolated from the peripheral blood
white cells of 76 individuals of Aotearoa New Zealand
Māori ancestry with varying serum urate levels.
Genome-wide methylation analysis was performed using
Illumina InfiniumMethylationEPIC BeadChips [32].
Fig. 1 IL-1β and IL-1Ra production after urate priming of PBMCs in vitro. Freshly isolated PBMCs from 85 healthy volunteers were exposed to
culture medium (RPMI 1640 supplemented with 10% human pooled serum) in the presence or absence of urate (UA) 10 or 50 mg/dL. After 24 h,
urate was removed, and cells were stimulated with LPS 10 ng/mL in the presence or absence of MSU crystals (300 μg/mL). IL-1β (A-B) and IL-1Ra
(C-D) were measured in the supernatants of cells, data are representative of 3 independent experiments using a total of 85 different healthy
volunteers of the 200FG cohort, graphs depict means+/−SEM. UA, uric acid/urate. *, Friedman test and post-hoc analysis p < 0.05
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Statistical analysis
Cytokine data were analyzed in GraphPad Prism version
8 using Friedmann or Wilcoxon signed rank test. ChIP-
sequencing and DNA methylation data were analyzed
using R.
Results
Urate treatment of human PBMCs in vitro results in a
specific and persistent cytokine production phenotype
We tested the effects of urate solubilized in culture
medium at high concentration (50 mg/dL) or at concen-
trations similar to in vivo hyperuricemia (10 mg/dL).
Both concentrations of soluble urate primed the cells to
produce higher IL-1β and lower IL-1Ra production
(Fig.1A–D). Next, we investigated whether these priming
effects persisted beyond the 24 h period of urate prim-
ing. Cells were incubated for 24 h with urate, washed,
and thereafter subjected to increasing resting times (up
to 5 days) in culture medium before stimulation with
LPS (10 ng/mL) and MSU crystals (300 μg/mL). While
IL-1β production capacity was strongly diminished after
48 h of culture (Fig.2A, B; 24 h resting periods and on-
wards), persistent effects were observed for reduction of
IL-1Ra (Fig.2C, D) and for induction of IL-6 (Fig. 2E, F).
Pharmacological inhibition of methyl-transferases inhibits
urate effects in an in vivo murine model of gout
The broad protein methyl-transferase inhibitor
methylthioadenosine (5′-S-methyl-5′-thioadenosine,
MTA) was previously shown to inhibit the cytokine
production induced by urate in vitro [21]. To provide
validation in an in vivo model, mice were adminis-
tered exogenous urate in addition to oxonic acid
(uricase inhibitor). Acute gout was induced by
Fig. 2 Persistence of urate priming effects in vitro. Freshly isolated PBMCs from 6 healthy volunteers were exposed to culture medium (RPMI
1640 supplemented with 10% human pooled serum) in the presence or absence of urate (UA) 50mg/dL. After 24 h, urate was removed, and cells
were stimulated with LPS 10 ng/mL in the presence or absence of MSU crystals (300 μg/mL). The second stimulation was performed at different
times after urate washout: immediately (0 h resting time), or after increasing the number of days of resting in 10% serum RPMI (24 h, 48 h, 5 days).
IL-1β (A-B), IL-1Ra (C-D), and IL-6 (E-F) were measured in the supernatants of cells, data are representative for 3 independent experiments and 6
different volunteers, graphs depict individual values with paired samples shown in identical symbols, bars and error bars represent means+/−SEM.
UA, uric acid/urate 50 mg/dL. *, Wilcoxon p < 0.05
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intraarticular injections with MSU crystals and
palmitate (C16:0). Inflammation was significantly en-
hanced in the oxonic acid group compared with con-
trols as observed by macroscopically scored
inflammation (Fig. 3A). The addition of MTA inhib-
ited this effect on the enhanced joint inflammation
and histology at 24 h post intraarticular injections
(Fig. 3A–C).
Histone 3 Lysine 4 trimethylation (H3K4me3) or Histone 3
Lysine 27 acetylation (H3K27ac) are mildly affected by
urate treatment of human monocytes in vitro
To test whether specific histone modifications are
associated with the persistent effects of urate priming,
we used chromatin immunoprecipitation coupled with
massively parallel sequencing (ChIP-seq) to profile the
enrichment of H3 histones trimethylated at lysine 4
(H3K4me3) and H3 histones acetylated at lysine 27
(H3K27ac), two transcriptionally permissive chromatin
modifications previously associated with long-term
effects of sterile stimul i[26].
The ChIPseq analysis was based on all dynamic genes
that were identified by comparing all samples to each
other. After filtering the data based on these cutoffs, no
clustering of stimulated samples was evident to indicate
that urate induced genome-wide significant differences on
these two histone marks (Fig.4A-D, Fig. S1) Nevertheless,
some individual genes, exhibited nominally-significant evi-
dence for variability for H3K4me3 (Table S2) or H3K27ac
(Table S3) enrichment at promoter regions. Of these, 12
genes (MED24, CSF3, TAF1C, DNAAF1, HCAR2,
ACO73072.5, IDO1, RP11-44 K6.2, RP11-370F5.4, RP11-
44 K6.5, SNRPC, and APOE) displayed variability for both
histone modifications in urate-primed cells compared to
control conditions (Fig. 4E, F).
DNA methylation profiling reveals candidates for effects
of serum urate levels in vivo in humans.
DNA methylation could also function as a basis for urate
imprinting as it is a stable epigenetic mark, often associ-
ated with long-term gene silencing. In the Aotearoa New
Zealand Māori participants, DNA methylation was de-
termined and assessed in whole blood samples of hyper-
uricemic and normouricemic volunteers. Approximately
850 K CpG sites were studied among the two groups
and revealed 223 differentially methylated probes
(difference in DNA methylation of at least 5%) (Fig. 5).
23 regions that exhibited significant differential methyla-
tion across the two groups of participants were found
both in intergenic or intragenic regions of specific genes,
one notable example being HLA-G (Fig. 5 B-C). Individ-
ual differentially methylated probes and differentially
methylated regions are listed in Table S4 and Table S5,
respectively. An expanded list of candidates was revealed
by data analysis of DNA methylation without cell com-
position correction (detailed information is provided in
the supporting information material, Fig. S2, Tables S6
and S7).
Discussion
In this study, we assess the effects of exposing PBMCs of
85 healthy participants to soluble urate at concentrations
of 10 mg/dL or 50 mg/dL in vitro. We show that both
concentrations induce a higher IL-1β release and a lower
IL-1Ra production in response to subsequent stimula-
tion with LPS or LPS+MSU crystals (Fig. 1). We also
Fig. 3 Methyltransferase inhibition limits gout inflammation in mice. Macroscopic (A) scores of the knees in mice treated with vehicle control or
oxonic acid + urate in the presence or absence of methyl transferase inhibitor MTA (methyl-thio-adenosine) followed by intraarticular injection of
MSU+C16:0. Inflammation was scored at 24 h. Histology (H&E staining) of joints treated with MSU+C16:0 in oxonic acid + urate mice (B) and in
the presence of MTA (C)
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describe persistent effects of the treatment with soluble
urate in primary myeloid cells that were treated with
urate for 24 h, followed by medium removal and stimu-
lation for another 24 h with LPS or LPS+MSU crystals
(in the absence of urate). The behavior of monocytes
after priming for 24 h with urate has been described pre-
viously, demonstrating that the cytokine production cap-
acity of the cells switches to higher IL-1β production
and lower IL-1Ra basal concentrations [21], by activating
AKT-PRAS40 and inhibiting autophagy [22]. Here, we
Fig. 4 ChIP-sequencing in urate-stimulated monocytes reveals no urate-dependent clustering based on phenotype for H3K4 trimethylation and
H3K27 acetylation. Cluster and principal component analysis of datasets obtained on ChIP-sequencing for H3K4me3 (A, B) or H3K27ac (C, D) in 4
different donors (labeled D1-4) and 4 different conditions (medium, urate, medium+LPS, urate+LPS). Venn diagram of regions showing differential
enrichment of either H3K27ac or H3K4me3 in urate primed cells (E) and list of overlapping genes based on histone marks at promoter regions,
including log 2 fold change values for each of the two histone marks (F)
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demonstrate similar effects of urate at 10 mg/dL as high
dose urate stimulations (50 mg/dL). Moreover, even after
extended resting times between priming and restimula-
tion, modified cytokine levels persisted in primary cells
exposed to urate. IL-1Ra remained downregulated after
48 h resting time (Fig. 2C, D). The increase in IL-6
remained present at all timepoints, although statistically
significant differences were only observed after 5 days of
Fig. 5 Differential DNA methylation in hyperuricemic versus normouricemic people. Principal component analysis of whole blood DNA
methylation data, obtained using Illumina InfiniumMethylationEPIC BeadChips in whole blood of 26 people with hyperuricemia compared to 50
normouricemic individuals (A). Differentially methylated regions (DMRs) at the HLA-G locus (B) and average DNA methylation levels (beta values)
for all CpG probes found within HLA-G (ticks on the x-axis represent individual probes and DNA chromosome position is indicated) (C).
Transcription factors are known to bind at the highlighted DMR1 and DMR3 regions according to the transcription factor ChIP-seq clusters from
ENCODE with factorbook motifs (D)
Badii et al. Arthritis Research & Therapy          (2021) 23:202 Page 7 of 11
rest in between stimulations (Fig. 2E, F). This may be
due to a limited number of donors and high variability.
Significant differences have been previously shown for IL-
6 in past reports on urate priming, with direct stimulation
at the end of the first 24 h of urate exposure [33, 21].
Other reports have shown that innate immune memory
induced by β-glucan, BCG or oxidized LDL particles is
best observed after 5 days resting intervals compared to 1
day rest or 3 days rest, possibly in connection with immu-
nometabolism changes (glycolysis induction associated to
innate immune memory) [34]. IL-1β induction upon
stimulation was, however, markedly reduced at later incu-
bation time points in all conditions (Fig. 1A, B). As op-
posed to monocytes which express constitutively active
caspase-1, in macrophages, the production of IL-1β is
more stringently regulated and needs two signals for ac-
tive IL-1β release: a PRR signal leading to proIL-1β tran-
scription and translation and an inflammasome activator
which leads to the proteolysis of proIL-1β into active IL-
1β [35]. Our results are in accordance with the restricted
IL-1β production in differentiated macrophages after lon-
ger in vitro culture of primary monocytes, due to inflam-
masome (caspase-1) inactivation [35].
Broad protein methylation inhibitor MTA was shown to
reverse the urate effect in vitro [21]. Here, we show reversal
of inflammation in an in vivo model of gout in mice (Fig. 3).
The pharmacological inhibition of the uricase enzyme using
oxonic acid is a commonly used model to assess hyperurice-
mia in animal models where the uricase gene functionality is
maintained [36, 37]. Previously, we have reported that oxonic
acid and urate treatment in mice enhances inflammation
triggered by intraarticular injections of palmitate and MSU
crystals [22]. In the current study, we show that this effect is
reversible in mice that were subjected to MTA treatment
prior to intraarticular injections, providing evidence that epi-
genetic modulators could be potential therapeutic agents for
the proinflammatory effects associated to urate exposure.
Given the broad effects of MTA, it cannot be excluded that
other processes, such as transcription factor methylation, are
at play in urate priming.
To further decipher the involvement of histone marks
in urate priming and persistence of effects, a genome-
wide approach was undertaken in the pursuit of asses-
sing epigenetic modifications globally. Two histone
marks were analyzed in the setting of urate priming: tri-
methylation of lysine 4 of histone 3 (H3K4me3) and
acetylation of lysine 27 of histone 3 (H3K27ac). Both
marks are associated with activation of gene expression
across different cell types [38], have been previously
studied in relation to other trained immunity stimuli in
recent reports [25, 39], and are known to be present at
the promoters of IL1B and IL1RN in monocytes [40].
The ChIPseq data (Fig. 4) shows a lack of sample clus-
tering based on urate exposure, indicating an absence of
genome wide effects for H3K4me3 and H3K27ac in this
experiment. Nevertheless, given the small number of
participants, targeted approaches at validating the hits
which showed evidence of variability are likely to provide
new understanding of urate-induced epigenetic effects.
Target genes that are relevant for urate-mediated effects
were identified in the histone modification datasets. The
IL1B and IL1A genes encoding the IL-1β and IL-1α pro-
inflammatory cytokines show enrichment of the
H3K27ac epigenetic mark, which is consistent with pre-
viously shown induction of these cytokines by urate
in vitro [21]. Twelve genes showed concordant variance
in both H3K4me3 and H3K27ac (Fig. 4E, F). Enrichment
of both histone marks was highest for MED24 (mediator
complex subunit 24), CSF3 (colony stimulating factor 3),
TAF1C (TATA-box binding protein associated factor,
RNA polymerase I subunit C), and DNAAF1 (dynein
axonemal assembly factor 1), while both marks were
downregulated for APOE (apolipoprotein E). APOE has
been previously associated to gout and hyperuricemia as
a potential link with hypertriglyceridemia, a common
finding in patients with gout [41]. APOE has also been
reported to coat MSU crystals and inhibit MSU-induced
inflammatory signaling [42]; therefore, the finding that
urate exposure can lead to a reduction in H3K4me3 and
H3K27ac (and, consequently, reduced chromatin acces-
sibility) at the APOE locus suggests that this effect could
be a point of study for the progression from hyperurice-
mia to gout. The validation of H3K27ac or H3K4me3
enrichment in response to lower concentrations of urate
or in patients with hyperuricemia would be a useful next
step. The fact that no differences are observed for LPS
stimulation in our dataset is intriguing and could be at-
tributable to the in vitro differentiation of the monocytes
into macrophages in the presence of serum-
supplemented culture medium. Serum is known to
downregulate CD14 expression and to induce the release
of CD14 in the extracellular space [43]. Moreover,
in vitro culture of monocytes for 24 h in standard condi-
tions is reported to lead to the irreversible loss of MD2
activity [44]. Taken together these data suggest that
serum-derived macrophages are less responsive to LPS
due to CD14 and MD2 downregulation in standard cul-
ture conditions, which may explain the lack of signifi-
cant alteration in the studied histone marks in response
to the short 4 h stimulation with LPS.
We also studied the possibility of DNA methylation
involvement in the proinflammatory effects associated to
hyperuricemia in a sample set of New Zealand Māori an-
cestry [28]. The Māori population has 2–3-fold higher
risk of gout compared to the population of European
descent[45], likely contributed to by genetic susceptibil-
ity alleles that have increased in prevalence during the
Pacific ancestral migrations, through mechanisms that
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are still debate d[46]. By comparing DNA methylation
status in hyperuricemic versus normouricemic volun-
teers within this cohort, 223 differentially methylated
probes and 23 differentially methylated regions were
identified in the vicinity of genes. Interestingly, three
DMRs were found to be present at the HLA-G locus
(human leukocyte-associated antigen, class I, G) (Fig.5).
Two of the HLA-G DMRs coincided with H3K27ac en-
richment peaks (Fig.5B), CD14+ monocyte DNAse I ac-
cessibility peaks (Fig. 5B) and binding sites for several
transcription factors (Fig. 5D) (www.encodeproject.org),
which is indicative of potential functional effects of the
DNA methylation variance observed at these sites. HLA-
G is a HLA-class Ib molecule with immunomodulatory
properties across several tissues, which has recently been
suggested to limit the progression of autoimmune and
autoinflammatory disorders (extensively reviewed in
[47]) and could be a promising target to study in gout.
Other candidates highlighted by the presence of two
DMPs in the vicinity of the gene (Table S4) were
IFITM3 (interferon-induced transmembrane protein 3)
or PRKAB2 (AMP-activated protein kinase subunit
beta 2, AMPK-β2). Genes in the interferon signaling
pathway have previously been reported to be differen-
tially expressed (upregulated) in whole blood of
healthy individuals administered rasburicase compared
to placebo [48]. In monocytes pre-treated with urate,
transcriptomic analysis revealed downregulation of
genes associated to GO term “Influenza A,” which in-
cludes several interferon signaling-related genes [22].
Moreover, type I interferons are known to inhibit
STAT1 signaling and inflammasome activation [49];
hence, urate-induced downregulation of interferon
signaling could play a role in escalating IL-1 produc-
tion and release. AMPK-β2 is a regulatory subunit of
AMP-activated protein kinase (AMPK). AMPK activa-
tion was shown to limit MSU crystal-induced IL-1β
production and to drive anti-inflammatory macro-
phage M2 polarization [50]. DNA hypomethylation at
the PRKAG2 gene body (AMPK subunit gamma 2)
was reported in gout patients compared to controls
[50]. Furthermore, PRKAG2 is one of the loci associ-
ated with hyperuricemia [12] and gout [51]. Our data
suggest that urate exposure could modulate AMPK
and interferon signaling pathways via DNA methyla-
tion in hyperuricemic people.
This report has the limitation of having studied a small
number of donors for the assessment of genome-wide epi-
genetic modifications (monocytes of 4 donors and stimula-
tions for ChIP-sequencing, or 26 versus 50 volunteers for the
DNA methylation study). Variation in histone modification
or DNA methylation in no gene was found to be
experimentally-wide significant between urate-exposed and
control. Nevertheless, there is evidence of variation
correlated to urate exposure for all these epigenetic mecha-
nisms in candidate genes. Further studies using larger sample
sizes or targeted approaches based on these initial candidates
are needed in order to find statistically significant effects.
Since this report describes consequences of higher than nor-
mal urate levels, we cannot exclude that any of these effects
could also be driven by the precipitated form of urate. For
the in vitro experiments, using polarized light microscopy,
we were not able to observe urate crystals formed during the
24 h of exposure time for the described experimental condi-
tions. Validating the changes in the histone mark landscape
at lower concentrations of urate or in patients with hyperuri-
cemia would be an important next step. Finally, the current
study lacks mRNA data to show transcriptional regulation of
cytokine genes in response to urate after differential resting
periods. A previous report by our group showed that the
gene expression of IL1B, IL1RN, and IL6 follows the same
trend as the protein levels at 24 h [22]. Further assessment of
the transcriptome of samples at later time-points after the
initial encounter with urate would help understand the ex-
tent of persistence of the transcriptional programme induced
by urate.
Conclusions
We have generated datasets involving epigenomic and
functional immunological experiments to investigate po-
tential major mechanisms involved in the urate priming
of myeloid cells. Based on complementary methods we
show that epigenetic changes are likely to play a role in
mediating the persistent effects of urate exposure on in-
nate immune cells. Our study shows that high levels of
urate can persistently alter the cytokine production cap-
acity of primary PBMCs in vitro, leading to increased IL-
1beta and IL-6 production and reduced levels of IL-1 re-
ceptor antagonist (IL-1Ra). Uricase inhibition in mice
led to higher inflammation scores upon intraarticular in-
jection of MSU crystals and palmitate, and this effect
was reversed by methyltransferase inhibition. We
present here evidence that histone modifications
(H3K4me3 or H3K27ac) and DNA methylation show
differences in response to high urate exposure and pro-
vide potential candidates of differentially regulated tar-
gets. The differences in epigenetic regulation may
provide a new understanding and possibility for inter-
vention in urate-dependent inflammatory responses as
well as in the progression from hyperuricemia to gout.
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